Following its previous recognition as a "2023 Deloitte China Pharmaceutical & Health Rising Star," Cygnus Bio has once again been selected as a "Deloitte China Rising Star" when the 2023 Deloitte China Top 50, Rising Star, and Tech Mu Lan Awards were announced on January 30, 2024. This successive recognition not only attests to Cygnus Bio's outstanding capabilities in R&D innovation and product services but also highlights the company's immense potential for future growth.
The Deloitte Technology Fast & Rising Star program is widely regarded as a benchmark for high-growth companies worldwide. The "Deloitte China Rising Star" award, a sister program to the "Deloitte Technology Fast 50," aims to recognize outstanding companies that have achieved leading positions in their respective segments and demonstrate substantial growth potential. Many industry leaders have emerged from past editions of Deloitte's high-growth programs. Cygnus Bio's ability to stand out among numerous enterprises underscores that its innovation capacity, growth potential, and corporate vitality have earned broad recognition from the industry.
The "2023 Deloitte China Pharmaceutical & Health Rising Star" program, a key subcategory of the Deloitte Technology Fast & Rising Star initiative, is designed to honor outstanding companies that hold leading positions in pharmaceutical and health sub‑sectors and exhibit significant growth potential. Since the program's launch at the end of June 2023, the review committee rigorously evaluated multiple dimensions – including financing valuation, founding team, technological innovation, market prospects, and industry ranking – and conducted on‑site verifications. Cygnus Bio secured its place on the list based on its comprehensive strengths.
As a representative original equipment manufacturer of gene sequencing instruments, Cygnus Bio has always taken innovation as its driving force. The company now holds foundational core patented sequencing technologies such as one‑step fluorogenic chemistry and triple error‑correcting code (ECC). It is a manufacturer of high‑throughput gene sequencing instruments with original, foundational gene sequencing technologies and full proprietary intellectual property rights, achieving comprehensive patent coverage across instruments, reagents, chips, and algorithms. The company's first sequencing system, the GS100, has already been launched.
Looking ahead, Cygnus Bio will continue to be driven by innovation, deepening its focus on customer needs. While optimizing its benchtop product series, the company plans to launch new gene sequencer product lines designed for high‑throughput, centralized clinical testing requirements and more intelligent operation. These efforts aim to provide simpler, more accurate, and more efficient gene sequencing tools and solutions for life sciences research – including biology, medical diagnostics, drug development, animal and plant breeding, customs inspection, disease control, forensic science, and evolutionary studies – thereby offering robust technical support for both research and clinical applications and contributing to improved public health.
